SMART VACCINES: A DECISION-SUPPORT TOOL
STAKEHOLDER FEEDBACK WORKSHOP
2 NOVEMBER 2012
National Academy of Sciences Auditorium
2101 Constitution Avenue NW, Washington, DC 20418

AGENDA
(Final; Last Updated: 31 October 2012)

9:30 AM  Welcome and Workshop Objectives  Lonnie King, Chair
9:40 AM  Sponsor’s Presentation  Bruce Gellin, Deputy Assistant Secretary of Health; Director, National Vaccine Program Office, Department of Health and Human Services
Study Task, Expectations, and Potential Use of SMART Vaccines

10:00 AM  SMART Vaccines: Update and Demonstration  Charles Phelps, Member

10:30 AM  Stakeholder Feedback Panel I

Moderator: Paul Citron, Member

- Carole Heilman, Director, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Disease, National Institutes of Health
- Melinda Wharton, Deputy Director, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention
- Marion Gruber, Director, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration
- Alexander Garza, Assistant Secretary for Health Affairs and Chief Medical Officer, Department of Homeland Security
- Robin Robinson, Director, Biomedical Advanced Research and Development Authority, Department of Health and Human Services
- Carter Diggs, Senior Technical Advisor, Malaria Vaccine Development Program, United States Agency for International Development
- Richard Martinello, Chief Consultant, Clinical Public Health, Department of Veterans Affairs
- David Hammer, Product Manager, Joint Vaccine Acquisition Program, Chemical Biological Medical Systems, Department of Defense
- Patricia Quinlisk, Medical Director, Iowa Department of Health
- Prasad Kulkarni, Medical Director, The Serum Institute of India Limited (via phone)
Noon   **Lunch** (available in the NAS Refectory)

1:00 PM **Stakeholder Feedback Panel II**
- **Rainer Engelhardt**, Assistant Deputy Minister, Infectious Disease Prevention and Control Branch Public Health Agency of Canada  
  Moderator: **Victoria Hale**, Member
- **Osman Mansoor**, Senior Health Advisor, New Vaccines, United Nations Children’s Fund
- **Joachim Hombach**, Senior Adviser, Department of Immunisation, Vaccines and Biologicals, World Health Organization
- **Ademola Olajide**, Head, Health, Nutrition and Population, Department of Social Affairs, African Union Commission (via phone)
- **Alex Palacios**, Special Representative, GAVI Alliance
- **Genevieve Meier**, Health Economics Manager, North America Vaccines Division, GlaxoSmithKline Vaccines
- **Diana Lanchoney**, Executive Director, Vaccine Ventures and New Products, Merck & Company
- **Seth Hetherington**, Chief Medical Officer, Genocea Biosciences; Member, National Vaccine Advisory Committee
- **Ann Ginsberg**, Vice President, Scientific Affairs, Aeras

3:00 PM **Break**

3:15 PM **Stakeholder Feedback Panel III**
- **Christopher Murray**, Director, Institute for Health Metrics and Evaluation, University of Washington School of Medicine (via phone)  
  Moderator: **Tracy Lieu**, Member
- **Peter Hotez**, President, Albert Sabin Vaccine Institute, and Dean, National School of Tropical Medicine, Baylor College of Medicine (via phone)
- **John Boslego**, Director, Vaccine Development Program, PATH
- **Phyllis Arthur**, Senior Director, Vaccines, Immunotherapeutics and Diagnostics Policy, Biotechnology Industry Organization
- **Jeffrey Sturchio**, Senior Partner, Rabin Martin
- **Irene Eckstrand**, Scientific Officer, Models of Infectious Disease Agent Study, National Institute of General Medical Sciences, National Institutes of Health
- **Timothy Lant**, Director, Analytic Decision Support, Biomedical Advanced Research
and Development Authority, Department of Health and Human Services

- Philip Eckhoff, Research Scientist and Principal Investigator, Disease Modeling Team, Intellectual Ventures (via phone)
- Robert Kolodner, Chief Health Informatics Officer and Acting Executive Officer, Open Health Tools

5:15 PM  Public Feedback and Comments  
Moderator: Tracy Lieu, Member

5:45 PM  Adjourn

QUESTIONS FOR DISCUSSION

1. **Usefulness**: Do you think SMART Vaccines could be useful to you as you make decisions regarding new vaccine development and prioritization? Please elaborate on how you might use it and for what purposes. How does this approach complement and/or differ from your current decision-making approach?

2. **Usability**: Does SMART Vaccines cover the most relevant issues related to vaccine development and prioritization? Is the current software version user friendly? Please comment on the ease of understanding how to use it, and the demands on the user.

3. **Data Library**: How should the committee address the intensive needs for data inputs into the model? How should the user groups think about data requirements and resources for data collection and standardization?

4. **Application Development**: In what ways can SMART Vaccines be enhanced?

5. **Outreach**: What advice can you give regarding how best to engage various user groups and decision makers to use—and further develop—SMART Vaccines?

For further information contact Kinpritma Sangha at ksangha@nas.edu or (202) 334-3346